Long-term Use of Antiepileptic Drug Vimpat( (Lacosamide) C-V Reduced Seizure Frequency and Severity and Improved Health-related Quality of Life Measures

Data presented at the 65th Annual Meeting of the American Epilepsy Society -- First presentation of pooled Vimpat® data showed a decrease in partial-onset seizure frequency and consistent efficacy in patients undergoing open-label treatment for up to eight years. -- Long-term treatment with Vimpat® was associated with statistically significant improvements in health-related quality of life standards, including seizure worry, social functioning, and overall health state. ...continued UCBJY

URL: http://www.investorpoint.com/news/INTHPINK/46625608/